Gulf International Bank UK Ltd Sells 2,390 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Gulf International Bank UK Ltd has reduced its stake in Alnylam Pharmaceuticals by 24.5%, now holding 7,364 shares valued at approximately $1.99 million.
• The company's stock has seen significant interest from institutional investors, with hedge funds owning nearly 93% of Alnylam's shares.
• Alnylam Pharmaceuticals recently reported an earnings per share (EPS) of $0.32, significantly beating analysts' expectations, while its quarterly revenue rose by 17.3% year-over-year.

Gulf International Bank UK Ltd lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 24.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,364 shares of the biopharmaceutical company's stock after selling 2,390 shares during the period. Gulf International Bank UK Ltd's holdings in Alnylam Pharmaceuticals were worth $1,988,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $28,000. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 71 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the last quarter. Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Finally, Washington Trust Advisors Inc. raised its stake in Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 61 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Raymond James Financial assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 target price for the company. JPMorgan Chase & Co. lifted their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Finally, BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a report on Tuesday, June 24th. Four investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $405.33.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $6.18 during trading on Friday, hitting $448.91. 713,353 shares of the company traded hands, compared to its average volume of 1,314,848. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The firm has a market cap of $58.84 billion, a P/E ratio of -181.74 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $449.52. The stock's fifty day moving average is $345.09 and its 200 day moving average is $290.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion during the quarter, compared to analyst estimates of $633.54 million. During the same quarter last year, the business earned ($0.13) earnings per share. The company's quarterly revenue was up 17.3% on a year-over-year basis. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the sale, the director directly owned 911 shares of the company's stock, valued at approximately $397,724.38. This represents a 97.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 82,385 shares of company stock worth $29,265,349. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.